Section Arrow
Quote
KALV.NASDAQ
- KalVista Pharmaceuticals
Quotes are at least 15-min delayed:2025/11/16 13:34 EST
Regular Hours
Last
 13.62
+0.53 (+4.05%)
Day High 
13.87 
Prev. Close
13.09 
1-M High
13.44 
Volume 
1.45M 
Bid
10.5
Ask
13.97
Day Low
12.95 
Open
13.13 
1-M Low
10.41 
Market Cap 
661.65M 
Currency USD 
P/E -- 
%Yield 2.05 
10-SMA 11.39 
20-SMA 11.28 
50-SMA 12.22 
52-W High 17.28 
52-W Low 7.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.94/-2.79
Enterprise Value
665.98M
Balance Sheet
Book Value Per Share
0.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed：2025/11/16 13:34 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.